Noxopharm Ltd. · ASX:NOX
Noxopharm — H.C. Wainwright 23rd Annual Global Investment Conference 2021
18 slides from Noxopharm's conference presentation, Sep 9, 2021
Slide 1: Noxopharm Updated Corporate Presentation (ASX Announcement)
For personal use only Noxopharm Limited (ASX:NOX) | ASX Announcement | 9 September 2021 Noxopharm Updated Corporate Presentation Sydney 9 September 2021: Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to provide an updated non-confidential corporate present
Slide 2: Forward Looking Statements
Noxopharm is running comprehensive drug discovery programs in both oncology and inflammation, and is the major shareholder of US biotechnology company, Nyrada Inc (ASX:NYR), active in the areas of drug development for cardiovascular and neurological diseases. To learn more, please visit: noxopharm.c
Slide 3: H.C. Wainwright 23rd Annual Global Investment Conference
For personal use only H.C. Wainwright 23rd Annual Global Investment Conference 13-15 September 2021
Slide 4: Disclaimer
For personal use only Disclaimer This presentation has been prepared by Noxopharm Limited (NOX or the looking statements contained in this document will actually occur or that the Company). It should not be considered as an offer or invitation to subscribe for, assumptions on which those statements
Slide 5: Complex diseases involve multiple errors; single-target therapies are limited
For personal use only Chronic cancer inflammation Human degenerative disease Autoimmunity Involves multiple mutations, Neurodegenerative diseases multiple errors Therapies targeting single errors Single drugs targeting multiple errors are restricted in their benefit OR The choice is polypharma Copyr
Slide 6: Introducing idronoxil (Veyonda)
Introducing For personal use only A novel multi kinase and membrane NAD(P)H-oxidase idronoxil (Veyonda®) inhibitor targeting aberrant protein behaviour Protein thiol- Protein Primary biochemical targets phosphorylation, Sphingomyelin disulfide dephosphorylation, pathway exchange dimerisation Primary
Slide 7: Four R&D Businesses in One Company
For personal use only Four R&D Businesses in One Company Veyonda® Cancer Research Veyonda® Pipeline Chronic inflammatory Cancer treatment Cancer growth Septic shock diseases/autoimmune enhancement factor inhibitors diseases Copyright Noxopharm 2021
Slide 8: Veyonda Cancer Treatment Enhancement Programs
Veyonda® For personal use only Cancer treatment enhancement IONIC - checkpoint inhibitor therapy DARRT - radiotherapy Programs A revolutionary concept in cancer therapy involving a drug (Veyonda®) with multiple CEP - chemotherapy mechanisms of action that aims to boost the effectiveness of other sta
Slide 9: Veyonda IONIC: Checkpoint Inhibitor Therapy
Veyonda® IONIC For personal use only Cancer treatment Checkpoint inhibitor therapy enhancement Idronoxil • Inhibits sphingosine Challenge kinase 1, blocking S1P • PD-1 inhibitor therapy production relies on the presence of • → upregulation of CD4+ effector T-cells to take and CD8+ T-cells advantage
Slide 10: Veyonda DARRT: External Beam Radiotherapy
Veyonda® DARRT For personal use only Cancer treatment External beam radiotherapy enhancement Challenge • Low-dose EBRT triggers an immune response within single irradiated Idronoxil tumours • On very rare occasions, • Inhibits autophagy Phase II DARRT trial • Activates immune function that immune re
Slide 11: Veyonda LuPIN: Radioligand Therapy
Veyonda® LuPIN For personal use only Cancer treatment Radioligand therapy enhancement Challenge Idronoxil • Effectiveness of targeted • Blocks cell division (G2M) radiotherapy by radioligands → greater DNA damage dependent on expression of • Blocks DNA repair LuPIN phase I/II study antigen target on
Slide 12: Veyonda CEP: Chemotherapy
Veyonda® CEP For personal use only Cancer treatment Chemotherapy enhancement Idronoxil • Blocks external membrane Challenge NADH oxidase function → High rates of inherent and interfers with protein folding acquired resistance in most • Blocks S1P expression → tumour types to cytotoxic chemotherapies
Slide 13: Cancer Research: 'Helper' Growth Factor Inhibitors
Cancer Research ‘Helper’ growth factor inhibitors For personal use only Pipeline Brain cancer (GBM) Programs Many cancers, particularly the Pancreatic cancer highly aggressive cancers, co- opt supporting healthy cells to supply growth factors that drive cancer cell growth. Noxopharm has identified a
Slide 14: Brain Cancer Program
Cancer Research For personal use only Pipeline Brain cancer program Noxopharm and U.S. National Cancer Institute to Collaborate on Promising New Approach to Treatment of Brain Cancer* Major discovery by NOX scientists of new family of molecules ➡ Killing brain cancer cells directly ➡ Blocking ‘helpe
Slide 15: Veyonda Septic Shock
Veyonda® For personal use only Septic shock Idronoxil • Potent inhibitor of cGAS- Phase I pilot trial completed STING /TBK1 signaling pathway → blocking • Hospitalised patients with moderate to release of pro- severe ARDS requiring supplementary O2 inflammatpry cytokines • Veyonda added to SOC • Upr
Slide 16: Chronic Inflammatory Diseases/Autoimmune Diseases
For personal use only Chronic inflammatory diseases/autoimmune diseases Chronic inflammation Pharmorage, a collaboration Programs between NOX and Hudson Institute of Medical Research. Autoimmunity Based on identification of a new family of drug compounds with highly selective activity against cGAS-S
Slide 17: Key Metrics and Anticipated News Flow
Key Metrics (at 8 September 2021) For personal use only Anticipated News Flow (next 6 months) Market cap A$153m Progress in IONIC-1, DARRT-2 & CEP-2 Share price A$0.53c Phase 2 COVID-19 clinical trial update Oncology drug pipeline progress Issued shares ~288.3m Pharmorage drug discovery progress Cas
Slide 18: For further information
For personal use only For further information: info@noxopharm.com www.noxopharm.com @Noxopharm
Noxopharm — H.C. Wainwright 23rd Annual Global Investment Conference 2021 on 6ix